Fattening the bankroll, Bill Haney adds cancer R&D powerhouse Merck to Skyhawk's roster of partners out to drug RNA
Whatever Biogen learned about Skyhawk in the 6 months since it anted up $74 million to get a collaboration going with their R&D team on drugging RNA for neurodegeneration, it must have been a positive experience.
The big biotech has already come back to the bargaining table and signed up to expand the range of targets on their discovery list. And this morning Skyhawk is also announcing that pharma giant Merck has stepped up with its own initiative on neurodegeneration while adding cancer to the RNA menu of collaborative specialties at the upstart drug discovery unit for the first time.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.